← All Signals

🏥 FDA: F.H. INVESTMENTS, Inc. (dba Asteria Health) — Class II

healthcarebearishSource: FDA
93%Confidence
0Views
FDASource
2026-03-02Date

Summary

Third testosterone pellet recall for Asteria Health confirms extensive quality system failures across their product line. The company now faces mounting regulatory pressure and potential product seizures that could threaten its ongoing operations.

Actionable: Avoid any business relationships with Asteria Health until they demonstrate resolution of their contamination issues through third-party verification.

AI Confidence: 93%

Data Points

firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 25.0 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-1025-32.

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now